Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | OAT | P04181 | 1/20 | 0.32 |
| ▸ | KMO | O15229 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.31 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL218876 | 0.86 | CYP19A1 (0.36) | HCAR2MAPTOATKMOAKR1C3 | |
| SCHEMBL5057907 | 0.86 | CYP19A1 (0.36) | HCAR2MAPTOATKMOAKR1C3 | |
| SCHEMBL28451456 | 0.86 | CYP19A1 (0.36) | HCAR2MAPTOATKMOAKR1C3 | |
| SCHEMBL4297167 | 0.80 | CYP19A1 (0.36) | AKR1C3AKR1C1 | |
| SCHEMBL5961832 | 0.80 | MAPT (0.35) | MAPTAKR1C3AKR1C1 | |
| SCHEMBL4315575 | 0.80 | CYP19A1 (0.33) | AKR1C3AKR1C1 | |
| Formic Acid SCHEMBL8030844 | 0.80 | CYP19A1 (0.33) | AKR1C3AKR1C1 | |
| SCHEMBL4700295 | 0.79 | CYP19A1 (0.31) | AKR1C3AKR1C1 | |
| SCHEMBL11910914 | 0.78 | — | — | |
| Maleic Anhydride SCHEMBL8030517 | 0.74 | CYP19A1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021110720-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2021-06-10 | — | — | WO | disclosed |
| US-20160251354-A1 | METHODS OF PREPARING INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED | 2016-09-01 | — | — | US | disclosed |
| EP-2861574-A1 | NEW BICYCLIC THIOPHENYLAMIDE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2015-04-22 | — | — | EP | disclosed |
| WO-2013189841-A1 | NEW BICYCLIC THIOPHENYLAMIDE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-12-27 | — | — | WO | disclosed |
| US-8232360-B2 | Stereoregular ROMP polymers | RESEARCH FOUNDATION OF STATE UNIVERSITY OF N.Y. (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232360-B2 | Stereoregular ROMP polymers | RESEARCH FOUNDATION OF STATE UNIVERSITY OF N.Y. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20110251363-A1 | STEREOREGULAR ROMP POLYMERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-10-13 | — | — | US | disclosed |
| US-20110251363-A1 | STEREOREGULAR ROMP POLYMERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-10-13 | — | — | US | disclosed |
| EP-1467979-B1 | FUSED HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2008-08-13 | — | — | EP | disclosed |
| US-7342034-B2 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-11 | — | — | US | disclosed |
| US-7291637-B2 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291637-B2 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291637-B2 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-7087636-B2 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-08 | — | — | US | disclosed |
| EP-1467979-A4 | FUSED HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF: MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20060020002-A1 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E | 2006-01-26 | — | — | US | disclosed |
| US-20050187273-A1 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E (US) | 2005-08-25 | — | — | US | disclosed |
| EP-1467979-A2 | FUSED HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF: MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | Bristol-Myers Squibb Company (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20030181728-A1 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-25 | — | — | US | disclosed |
| WO-2003053358-A2 | FUSED HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF: MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020002-A1 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NR5A2, NR5A1 | HCAR2 109/4885MAPT 4333/4885OAT 3515/4885 |
| US-20050187273-A1 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NR5A2, NR5A1 | HCAR2 109/4885MAPT 4333/4885OAT 3515/4885 |
| US-20030181728-A1 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NR5A2, NR5A1 | HCAR2 109/4885MAPT 4333/4885OAT 3515/4885 |
| US-20160251354-A1 | METHODS OF PREPARING INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ZC3HAV1, ZC3HAV1L, POLR2H | HCAR2 4796/4885MAPT 3742/4885OAT 1519/4885 |
| US-20110251363-A1 | STEREOREGULAR ROMP POLYMERS | PCBP1, PARG, OSGEP | HCAR2 2409/4885MAPT 1131/4885OAT 3700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.